Abstract: Intensivists routinely administer glucocorticoids, which are potent anti-inflammatory, immune, metabolic, and adrenergic modulating compounds at physiologic and pharmacologic doses. Recent investigations report increasing recognition of relative or absolute adrenal insufficiency in critically ill patients and the impact of cortisol responsiveness as a predictor of outcome for the critically ill. Several meta-analyses of studies from the 1970s and 1980s identified the lack of efficacy of "industrial" bolus doses of glucocorticoids (30 mg/kg of methylprednisolone or 6 mg/kg of dexamethasone) for short periods to treat septic shock patients within hours of diagnosis. Similarly, a large dose pulse therapy trial during the early evolution (exudative phase) of acute respiratory distress syndrome (ARDS) showed no benefit. Physiologic supplementation with glucocorticoids for refractory septic shock appears to be increasingly accepted, whereas pharmacologic steroid therapy during the fibroproliferative phase of ARDS remains under active evaluation. Therefore, this review discusses current rationales and evidence-based recommendations for acute glucocorticoid therapy in the critically ill, with specific focus on the need for steroid replacement therapy during critical illness or procedural stress.
G lucocorticoids play a crucial role in the maintenance of homeostasis through their effects on metabolism, circulatory function, immune responsiveness, and thermoregulation. [1] [2] [3] [4] [5] The clinical introduction of purified adrenocorticotropic hormone (ACTH or corticotropin) and cortisone, the first glucocorticoid preparation, in 1949 led to major advances in the care of patients with adrenal insufficiency, as well as those with various autoimmune and inflammatory processes, and provided a foundation for modern chemotherapeutic regimens and organ transplantation. 6, 7 However, shortly after the introduction of glucocorticoids, reports of various steroid-induced adverse effects appeared (Table 1) . 8, 9 Two sentinel cases describing deaths during the perioperative period were reported in steroid-dependent patients who did not receive glucocorticoid therapy before or during surgery. 8, 9 These reports led to empiric recommendation of "one size fits all" glucocorticoid replacement for steroid-dependent patients during acute illness or intervention. Throughout the past 25 years, various investigations have challenged this dogma and recommended tailoring of doses appropriate to the chronic dose of glucocorticoid ingested, duration of steroid administration, degree of physiologic stress, and the duration of ongoing insult. Investigators also recently recognized the potential for either undiagnosed relative or absolute adrenal insufficiency or unresponsiveness to cortisol in various patients, particularly the elderly and septic patients. 10 -20 Intensivists have long speculated that glucocorticoids are potential positive therapeutic tools in altering the natural history of various pathophysiologies through modifications of endogenous inflammation, cell signaling, and glucocorticoid receptor function and gene expression. [21] [22] [23] [24] [25] [26] [27] [28] Critically ill patients with known or suspected relative or absolute adrenal insufficiency frequently receive acute physiologic replacement of glucocorticoids. 10, 17, 29 Pharmacologic doses of glucocorticoids are commonly administered to critically ill patients as part of chronic maintenance therapy for autoimmune or inflammatory diseases. Pharmacologic doses are also administered for acute exacerbations of chronic diseases, such as chronic obstructive pulmonary disease (COPD), reactive airway disease, or lupus nephritis. Pharmacologic doses may be administered for specific therapy for diseases encountered mainly in the intensive care unit (ICU), including the fibroproliferative phase of ARDS, acute spinal cord injury, bacterial meningitis, and Pneumocystis carinii pneumonia (Table  2) . 30 -34 In the 1970s and 1980s, intensivists administered "mega" or industrial doses, defined as 30 mg/kg of methylprednisolone or 6 mg/kg of dexamethasone as frequently as every 6 hours, usually for 24 -48 hours to patients with "severe sepsis/septic shock" and patients during the acute onset of ARDS. [21] [22] [23] Jacob and colleagues provided the rationale for such high-dose corticosteroids when they showed that glucocorticoids favorably modulated complement activation and white cell stasis in shock states in animal models. 24 Despite initial enthusiasm, several large, randomized, prospective clinical trials reported a lack of efficacy or survival in patients treated with such doses. [21] [22] [23] Two metaanalyses strongly discouraged the use of such therapies in septic patients. 25, 26 However, many intensivists still wondered whether they were administering the right drug but at the wrong dose at the wrong time and for an incorrect duration. 27, [35] [36] [37] [38] Therefore, questions remained about the potential benefits of physiologic or slightly supraphysiologic steroid therapy in septic shock or the pharmacologic, antiinflammatory effect of steroids in the fibroproliferative phase of ARDS. 30,31,36 -38 This review discusses the normal production and function of corticosteroids and the effects on corticosteroid synthesis and responsiveness in acutely stressed and critically ill patients encountered on a day-to-day basis in the perioperative period or ICU. The evidence for rational replacement dosing in patients with known and suspected adrenal insufficiency (AI), patients who appear to be underresponsive to glucocorticoids, and patients whose pathologies may be steroid responsive follows.
Modulation of Adrenocorticoid Steroid Production and Function
Synthesis of cortisol, a cholesterol derivative and the major endogenous glucocorticoid, occurs in the zona fasciculata of the adrenal cortex. 1, 39, 40 Cortisol production is under tight neurohormonal regulation through a negative feedback system under control of the hypothalamus (corticotropin releasing hormone [CRH] and pituitary ACTH; see Figure 1 ). This hypothalamic-pituitary-adrenal axis (HPA) can be disrupted at any of the 3 sites of hormonal production or action, as well at the cellular level at the glucocorticoid receptor and gene level. The adrenal cortex normally manufactures approximately 5-10 mg/m 2 of cortisol per day, corresponding to 20-30 mg of hydrocortisone per day or 5-7 mg of prednisone per day. 39 -41 Production is diurnal, greatest in the early morning between 4 and 8 a.m. and lowest later in the evening. This diurnal variation is frequently disrupted during acute illness or after surgery. 40, 42, 43 Maximal stress production of cortisol is 60-100 mg/m 2 per day (150-300 mg of hydrocortisone or 30-60 mg of prednisone/day).
Synthesis of aldosterone, the main mineralocorticoid, occurs in the zona glomerulosa under the control of the renin-angiotensin system. 39 Aldosterone facilitates sodium and potassium homeostasis and maintenance of intravascular volume. 39,44 -46 Although less potent than aldosterone, cortisol has mineralocorticoid activity that is greater than increasingly potent synthetic glucocorticoids listed in Table 3 .
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Relative or Absolute AI Table 4 outlines the characteristics of primary, secondary, or tertiary AI. 1 The development of relative (insufficient production of glucocorticoids, inadequate increase in production with stress, or insufficient response to endogenous steroid production) or absolute (no glucocorticoid formation, as occurs in bilateral adrenal hemorrhage) AI may be acute or chronic. 1 Primary AI is relatively rare (approximately 0.01% of the population) and develops in patients who have sustained more than 90% destruction of the adrenal glands, most commonly secondary to autoimmune adrenalitis. 1, 39, 44 Other causes of primary AI include infection, hemorrhage, infarction, or replacement by tumor, inflammation, or fibrosis. Acute primary AI may develop in patients receiving anticoagulation or those with severe shock. Patients with primary AI are both glucocorticoid and mineralocorticoid deficient (see Tables 3 and 4) . 1, 39, 44 Secondary AI develops when a patient has insufficient production of ACTH, which is caused by destruction or dysfunction of the pituitary or hypothalamus. In the critically ill, this deficiency occurs most often in closed head injury patients or patients undergoing neurosurgical procedures such as pituitary resection. 1, 39, 44 Some refer to secondary AI developing when ACTH production is diminished by cytokine and proinflammatory inhibition, but we include that in the tertiary class of AI. 1, 44 Tertiary AI is by far the most common cause of adrenal dysfunction. 1, 39 In the general population, tertiary AI is most commonly caused by iatrogenic administration of exogenous glucocorticoids (see Table 4 ) that results in suppression of the HPA axis, whereas cytokine-mediated depression of ACTH production results in tertiary AI, most frequently in the critically ill. Adrenal gland atrophy develops in tertiary AI from chronic suppression of ACTH if the dose and duration of exogenous glucocorticoids is sufficient. The actual dose of steroids and duration of steroid therapy resulting in adrenal hyporesponsiveness or atrophy is variable, however, and somewhat unpredictable. Several investigators have identified a significant relative mineralocorticoid insufficiency during critical illness. 45, 46 This hyperreninemic hypoaldosteronemia occurs in Ͼ 20% of critically ill patients, particularly in hypotensive patients. Therefore, some investigators advocate the administration of fludrocortisone in selected cases of AI in the critically ill (see Steroids in Septic Shock).
29

Use of Serum Cortisol and Cosyntropin Stimulation Testing in the ICU
Although previously felt to be unambiguous, testing of adrenal reserve and function of the HPA axis may be challenging (Table 5) . 2, 43, 47 Conventional wisdom stated that measurement of a morning or random cortisol that reported a level Ͼ 25-30 g/dL was consistent with adequate adrenal 
Indication Comments
Sepsis-induced hypotension/shock Y Recent placebo-controlled, randomized, double-blind study in 299 septic vasopressor dependent patients from 19 French ICUs is the largest report to date. Trial used a short cosyntropin stimulation test to identify adrenal insufficiency or hyporesponsiveness as defined by an increase of Ͻ9 g/dL after stimulation independent of baseline level of cortisol. This was present in 80% of patients (29) . Y Supplemented with a dose equivalent to physiologic "stress" replacement. Hydrocortisone 50 mg intravenous (IV) q 6 h and 50 g of fludrocortisone per nasogastric tube (NG) for 7 days. Y Study showed faster discontinuation of vasopressors and improved outcome in patients who had an inadequate cosyntropin stimulation. Y Other smaller studies used a 100-mg load followed by a continuous infusion at 0.18 mg/kg/h or 100 mg hydrocortisone IV q 8 h. Steroids were tapered after a week or as the patient stabilized and improved hemodynamically, with doses tapered over days to a week or so in these studies (51, 55) .
Fibroproliferative phase of ARDS Y Patients who survive initial respiratory event and exudative phase of ARDS often have an ICU course complicated by the development of abnormal lung repair (fibroproliferative phase of ARDS) and multiple organ dysfunction secondary to systemic inflammation and abnormal lung repair. Y Experimental therapy at present. ARDS network currently performing a national multicenter trial (31) . Y Modest-sized case series and 1 small multicenter randomized prospective controlled trial (RPCT) report benefit (30) . Y Administer at around 7-10 days in patients with severe, persistent ARDS. Y Benefit appears to be limited if steroids discontinued prematurely. Start with 2 mg/kg of IV load.
Then 2 mg/kg per day (methylprednisolone) in 4 divided daily doses for 2 weeks, then 1 mg/kg for 2 weeks, then 0.5 mg/kg/day for a week, followed by 0.25 mg/day for 2 days, and then 0.125 mg/kg/day for 2 days, and then discontinue (31, 36) .
Acute spinal cord injury
Y Still open to debate by some about whether data support this as being a standard of care (32, 64) . Severe typhoid fever with shock Y Methylprednisolone IV or prednisone po 50-100 mg/day and then tapered as shock resolves (72). responsiveness. 39 However, this assumption may not be valid in patients with adrenal hyporesponsiveness, as described in some elderly patients and patients with vasopressor-dependent septic shock (see Steroids in Sepsis). 29, 48 Investigators have also reported the predictive value of serum cortisol and cosyntropin stimulation and patient outcome with sepsis. 43, 48 In contradistinction to previous studies that reported poorer outcome in patients with overt AI or excessive stress-induced cortisol levels, Annane et al 48 reported correlation to outcome in septic shock patients with the incremental increase after cosyntropin stimulation and absolute cortisol level (see Steroids in Sepsis).
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Historically, the use of a supraphysiologic stimulation of the adrenals with the routine 250 g cosyntropin stimulation resulting in an increase from baseline to Ͼ 30 g/dL was previously considered to be consistent with adequate HPA reserve. 44, 49 The incremental change from baseline appears to be important, with a "normal" response being Ͼ 9 g/dL. Septic patients, for example, with low cortisol levels despite stimulation or Ͻ 9 g increase from any baseline level during 250 g cosyntropin stimulation have compromised outcomes. 29, 48 None of the current stimulatory protocols address actual modulation of glucocorticoid receptor response by acute illness and the interaction of glucocorticoids with key intracellular signaling systems (see Fig. 1 ). Recent data also call into question the potential benefit of more physiologic adrenal stimulation using a 1 g cosyntropin bolus with follow-up levels at 30 and 60 minutes. 44, 49 Although the adrenals may respond to the supraphysiologic 250-g cosyntropin stimulation, it may not represent a clinically relevant response. 49 Further data about the utility of the 1-versus 250-g cosyntropin stimulation test is needed before the current high-dose standard is replaced.
Perioperative Glucocorticoid Replacement in Patients Receiving Chronic Steroids
In the early 1950s, several reports described surgical patients who were chronically treated with preoperative steroids but did not receive them during their respective perioperative periods. 8, 9 Although the cause and effect of acute AI are debatable in this case, these reports led to treatment guidelines proposed by Lewis et al 9 for perioperative patients requiring exogenous glucocorticoids. These guidelines quickly became the standard of therapy, albeit based on limited anecdotal experience with this approach. The recommended empiric glucocorticoid replacement dose was potentially excessive, with little regard to the duration of dosing, total daily dose, stress of the surgery, or the ability to evaluate the HPA and cortisol production.
These initial conventional guidelines called for administration of stress steroid doses (approximately 200-300 mg of hydrocortisone or 40-60 mg of prednisone per day) that are higher than the endogenous stress response associated with surgery or acute illness. 10 This dosing regimen also mandated slow tapering over several days to a week. Throughout the ensuing years, this led to concerns for impaired wound healing; suppressed immune function; and abnormalities in glucose metabolism and thermal regulation. Consequently, several investigators challenged the practice of empiric, high-dose replacement therapy and proposed the development of more rational, datadriven recommendations (see Table 6 ). 10, 17, 18, 50 In a series of reports in the mid-1970s, various investigators reviewed the lack of evidence for compromise of Consider initially performing a low-dose cosyntropin stimulation with 1 g* and 30-and 60-minute postcortisol levels.
*This is more physiologic than the high dose, and if the response is appropriate to the clinical situation, consider other etiologies or hypothalamic or pituitary pathology.
If a low-dose stimulation is equivocal, perform a high-dose cosyntropin stimulation with 250 g, recognizing that this may generate a false-negative test.
Normal response with appropriate increase in cortisol with stimulation (Ͼ9 g/dL). Current recommendations are to leave alone and not treat (see below**). **The adrenal glands may be intact, but anterior pituitary or hypothalamus are not functioning normally, which may be differentiated on a case-by-case basis by selectively performing a plasma ACTH level, CRH-ACTH stimulation, prolonged ACTH stimulation test, or other challenge to the hypothalamicpituitary part of the HPA axis, such as an insulin tolerance test. **It may take time for adrenal dysfunction (10 -14 days for the adrenals to begin to atrophy if ACTH or CRH levels are inadequate) or glucocorticoid resistance to develop. Therefore, if a patient remains hemodynamically unstable, vasopressor dependent, or otherwise compromised secondary to potential adrenal inadequacy glucocorticoid unresponsiveness, reinterrogate the HPA axis.
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Clinical Pulmonary Medicine • Volume 10, Number 5, Sept-Oct 2003 perioperative outcome in general surgical, cardiothoracic, orthopedic, and urologic patients who received glucocorticoids long-term but did not develop acute adrenal crisis secondary to inadequate perioperative glucocorticoid therapy. 11, [13] [14] [15] [16] In a retrospective study of almost 7,000 patients who received glucocorticoids long-term and underwent urologic procedures without routine steroid supplementation, there was only 1 case of clinically significant perioperative AI (0.01%). 14 Alford et al 15 performed a similar evaluation in more than 4,300 patients undergoing major cardiothoracic surgery. These investigators only identified 5 cases of postoperative AI according to clinical criteria. 15 Finally, Kehlet 13 carefully reviewed 57 case reports throughout a 25-year period of perioperative shock or death in patients taking chronic glucocorticoids. The morbidity and mortality in these cases were suspected to be secondary to stress-induced AI developing within 48 hours postoperatively. Only 3 of 57 patients had hypotension along with low plasma cortisol levels consistent with AI, whereas the remainder of cases were inconclusive or had no direct evidence of hypoadrenalism. 13 Current guidelines for the appropriate administration of supplemental glucocorticoids are based on the work of Kehlet et al, Salem and colleagues, and others. 10, 17, 18 The doses and duration of dosing are outlined in Table 6 and are individualized to the patient and the degree of stress, surgical stimulation, or acute illness. Additional steroids can be administered as needed if patients appear to have unmasked AI despite appropriate hydration, temperature maintenance, and electrolyte and acid-base correction.
Steroids in Sepsis and Septic Shock
Sepsis remains the leading cause of death in the ICU. 29 Dosing, duration of dosing, and identification of septic patient population(s) who might benefit from the administration of steroids continues to consume significant investigative resources. 29, [51] [52] [53] [54] [55] [56] Current investigations revisited perioperative and ICU AI secondary to sepsis induced hypotension or shock. 29, 56 These cases of AI may be due to decreased production of glucocorticoids secondary to decreased corticotropin releasing hormone and ACTH, diminished adrenal function, and synthesis of cortisol (referred to as occult AI or adrenal exhaustion syndrome), or peripheral underresponsiveness to cortisol and hyporesponsiveness to adrenergic receptors. 38 Rivers et al 56 described a "transient" AI developing in elderly surgical patients with sepsis and hypotension. In a prospective, observational study, Rivers and colleagues evaluated 104 elderly patients with a mean age of 65.2Ϯ16.9 years who underwent surgery and were admitted to the ICU with hypotension despite adequate fluid resuscitation. All of the study patients required treatment with vasopressors. A high-dose synthetic ACTH (cosyntropin) stimulation test with 250 g was performed after measurement of baseline cortisol and poststimulation cortisol measurements at 30 and 60 minutes. AI, defined as baseline serum cortisol Ͻ 20 g/dL, with an increase in cortisol of Ͻ 9 g/dL after stimulation, or functional hypoadrenalism identified by a serum cortisol Ͻ 30 g/dL with change in cortisol of Ͻ 9 g/dL, was present in almost a third of patients (32.7%), which is appreciably higher than predicted for the general surgical population. Although these patients may not be at risk for an acute adrenal crisis, they appeared to benefit from supplemental steroids. 56 Recently, Annane and colleagues 29 performed a French multicenter, randomized, prospective, double-blind study in 299 patients. Septic shock patients who were vasopressor and fluid dependent for less than 8 hours were studied. They were identified as cosyntropin stimulation (250 g) responders (Ͼ 9 g/dL after cosyntropin) or nonresponders (Ͻ 9 g/dL).
All patients were then randomized to receive intermittent intravenous boluses of hydrocortisone and daily enteral fludrocortisone or placebo. Treated patients who were nonresponders had faster recovery and improved survival. It is important to emphasize that responders who were treated with glucocorticoids had no benefit and may have been compromised by steroid therapy. Annane et al 29 emphasized the following reasons for the benefit of combined glucocorticoid and mineralocorticoid therapy:
1. It occurred in a targeted population, septic shock patients who were nonresponders to a 250-g cosyntropin (high-dose) stimulation test;
2. Addition of a fludrocortisone may have treated a relative mineralocorticoid deficiency; and 
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3. Prolonged dosing (1 week) may limit the reported rebound systemic inflammatory response syndrome that occurs when steroids are too quickly discontinued. 29 Interestingly, the intent-to-treat benefit was 1 in 7 patients, which compared favorably to the 1 in 16 patients needed to be treated to improve outcome in the recent activated protein C in sepsis trial. 29, 57 In the editorial that accompanied the study by Annane and colleagues, Abraham and Evans 53 emphasized several important points concerning the lack of adrenal reserve in the ICU patient. First, absolute AI is uncommon, but relative AI occurs frequently. Second, supplementation in a well-defined subgroup of patients, those nonresponders with septic shock and receiving vasopressors for less than a week, resulted in improved survival. Third, more information is needed about the role of steroid supplementation in septic shock patients. The editorialists called for improved characterization of groups likely to benefit from exogenous steroids, as well as larger observational studies to identify the true incidence of adrenal underresponsiveness in critical illness. They also anticipated more data on the relationship of severity of illness to outcome in steroid-treated patients and precise dose and composition of steroid supplementation to be used. The authors highlighted the fact that in the study by Annane et al, 29 normal responders to cosyntropin stimulation who were treated with steroids appeared to have a compromise in outcome. 53 They advocated the avoidance of steroid supplementation or discontinuation in patients who had a Ͼ 9 g/dL response to a 250-g cosyntropin stimulation. Abraham and Evans 53 pondered the potential changes in outcome in septic shock patients if glucocorticoid supplementation were combined with other recently identified beneficial measures, such as infused activated protein C or the use of protective ventilatory strategies. However, they also raised concerns that exogenous steroid administration might result in higher glucose levels and make it more difficult to maintain euglycemia, recently shown to improve outcome in critical illness. 52, 53 The proposed mechanisms for the beneficial effects of steroids in sepsis are classified under immune modulation/ anti-inflammation and improved vascular bed responsivity. 36 -38 Glucocorticoids prevent inflammatory cell migration and block synthesis of various proinflammatory cytokines (chemokines, interleukins), adhesion molecules, and cyclooxygenase products while acting synergistically with various anti-inflammatory mediators. 36 -38 Steroid supplementation in septic shock appears to restore adrenergic responsiveness, improve renal blood flow, and increase vessel wall electrolyte homeostasis. Table 2 outlines the rationale and a brief therapeutic description of pharmacologic use of glucocorticoids for acute illnesses. The administration of pharmacologic doses of glucocorticoids in various critically ill populations remains under investigation.
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Pharmacological Administration of Glucocorticoids in Critical Illness
ARDS
Meduri and colleagues 30, 36 have championed administration of protracted pharmacologic doses of glucocorticoids in patients with fibroproliferative ARDS. This led to the ongoing ARDS network-sponsored late steroid rescue study. 31 This randomized, placebo-controlled, double-blind, multicenter trial has been ongoing for about 2 years and has enrolled approximately 80% of the projected 180 patients.
The rationalization for steroid efficacy in delayed ARDS centers on host response to inflammation and endogenous glucocorticoid production, potential exaggerated host response and subsequent glucocorticoid resistance, and need in selected patients for extended glucocorticoid therapy to provide disease resolution. 36 Several anecdotal reports and 1 small single-center trial reported improved outcome in patients who had persistent ARDS and were treated with glucocorticoids. 31, 36 The major concerns with this therapy are proper identification of the subset of patients who require such therapy, appropriate dosing, and optimal duration of glucocorticoid therapy. Because the goal of therapy is to positively modulate excessive inflammation and blunt lung collagen synthesis, improve lung water homeostasis, and enhance glucocorticoid responsiveness, Meduri and Kanangat 36 have eloquently argued that therapy needs to be of sufficient magnitude and duration to suppress proinflammatory mediators, enhance anti-inflammation, and avoid rebound inflammation.
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Acute Spinal Cord Injury
Several multicenter, prospective, randomized trials (National Acute Spinal Cord Injury Study II, III, and others) performed within the past 15 years evaluated the use of 24 -48 hours of continuous infusions of methylprednisolone in patients with acute spinal cord injury. 62, 63 The theoretical neuroprotective bases for steroid infusion in acute spinal cord injury include inhibition of lipid peroxidation; alteration in calcium influx; limitation of ischemia, axonal dieback, cytoskeletal degradation; and anti-inflammatory effects. 32, 64 A contentious debate continues, however, within the spine community about the statistical basis for advocating steroid therapy and potential steroid-induced adverse effects. 32, 65 The most recent recommendations from the Spine Society, although not unanimous, are that 24-to 48 
Meningitis
The use of short-term glucocorticoids to limit meningeal inflammation and improve neurologic outcome and survival has been an ongoing debate throughout the past 2 decades. Part of the controversy has centered on study design, population studied (children versus adults), timing and duration of steroids, and causative pathogen. However, a recent multicenter trial reported significant improvement in outcome for adults with bacterial meningitis treated with dexamethasone 6 mg every 6 hours for 4 days. 33,66 -69 Three hundred one well-matched patients were randomized to treatment or placebo. Dexamethasone was administered starting 15-20 minutes before antibiotic treatment or concurrently. Mortality was reduced for dexamethasone-treated patients, and survivors had better neurologic recovery than the control group. In particular, dexamethasone treatment halved the mortality in patients who had pneumococcal meningitis, the most common cause of bacterial meningitis in immunocompetent adults. Dexamethasone did not result in an increased incidence of gastrointestinal bleeding. An accompanying editorial to this article supported the use of dexamethasone immediately before antibiotic treatment in patients with pneumococcal meningitis but cautioned about the potential for its inhibition of the effectiveness of vancomycin, a static glycopeptide that does not penetrate the meninges unless they are inflamed. Some researchers suggest the use of glucocorticoids in children with meningitis, particularly those with Hemophilus influenza, an organism significantly decreased in prevalence with the advent of widespread immunization programs. 33 
Current Recommendations and Conclusions
Historically, recommendations for glucocorticoid replacement therapy were empiric and based on limited anecdotal experience. Previous guidelines did not take into account the dose or duration of previous glucocorticoid therapy nor were they adjusted to the degree of stress. The speed with which adrenal suppression develops in patients receiving exogenous glucocorticoid therapy may be unpredictable. Current recommendations (Table 6 ) suggest that patients who ingest steroids daily continue to receive their normal dose as a minimum on the day of surgery or during acute illness. Patients receiving Ͼ 5 mg of prednisone for a sufficient period should be treated with adjusted doses of supplemental glucocorticoids (Table 6) . Patients with Addison disease should always receive at least maintenance therapy and graduated amounts of supplementary therapy, depending on the stress. If they are treated with sufficient doses of hydrocortisone (Ͼ 50 mg/day), they do not need supplementation with fludrocortisone routinely. Patients who require physiologic supplementation because of AI rarely, if ever, require more than 150-200 mg of hydrocortisone or its equivalent glucocorticoid or mineralocorticoid per day.
Testing of the HPA axis can be readily performed by using a short-term cosyntropin stimulation. The optimal dose of cosyntropin remains open to debate, however. Patients who have normal adrenal reserve but central deficiency in CRF or ACTH production are not identified with cosyntropin stimulation. More sophisticated testing with measurement of serum ACTH levels or CRF-ACTH stimulation testing may be required on a case-by-case basis. If stress steroids are administered before or during cosyntropin stimulation, dexamethasone is the glucocorticoid of choice because it is not metabolized to cortisol or an end metabolic product that alters cortisol measurement. There are no means to assess directly peripheral cortisol response or glucocorticoid receptor function.
Overt absolute AI remains uncommon, but inadequate adrenal response during critical illness is increasingly recognized, particularly in the elderly and in septic patients. In addition, an imbalance in the normal proinflammatory and anti-inflammatory response to acute illness, glucocorticoid hyporesponsiveness in some critically ill patients, and ongoing repetitive inflammatory insults during the ICU course led to recent and ongoing investigations in the efficacy of modulating these events with physiologic or pharmacologic corticosteroid therapy. 38 The appropriate role of glucocorticoids in patients with sepsis-induced hypotension and vasopressor dependence has been intensely investigated throughout the past decade. In contrast to the previous studies that reported no benefit with short-term massive doses of glucocorticoids in septic patients, a recent multicenter trial reported improvements in ICU course and lessened mortality in a subset of septic shock patients who had a relatively inadequate response to cosyntropin stimulation. 29 Data should also be forthcoming in the near future on the potential role of glucocorticoid rescue therapy during the fibroproliferative phase of ARDS. 31 
